Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Fosun Pharmaceutical is moving forward with the proposed privatization of Shanghai Henlius Biotech through a merger by absorption. The company has dispatched a composite document outlining the merger details, including the expected timetable and recommendations from the Independent Board Committee. Shareholders are advised to review the terms and consider their options between the Cash Alternative and Share Alternative.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
